The relationship of long-term persistence of antiphospholipid antibodies with clinical and laboratory risk profile in women


DOI: https://dx.doi.org/10.18565/therapy.2020.1.52-58

Vereina N.K., Chulkov Vas.S., Chulkov Vl.S., Movchan T.V.

South Ural State medical University of the Ministry of Healthcare of Russia, Chelyabinsk
Purpose: to estimate the power of correlation between the persistence of autoantibodies to phospholipid-binding blood proteins (AFL) for more than 12 weeks in females with an initial point score on the aGAPSS scale, the fact of «double» and «triple» positivity in the first identification, as well as with the presence of thrombotic and obstetric complications in anamnesis..
Material and methods. A total of 117 women were included in the case-control study: 44 patients with persistence ≥1 type of antiphospholipid antibodies (APA) for 12 or more weeks were assigned to the «сases»; 73 patients with transient circulation of APA less than 12 weeks were assigned to the «сontrol».
Results and conclusion. An initial examination of women with a subsequent persistence of antiphospholipid antibodies ≥12 weeks compared with their transient circulation revealed a higher incidence of arterial and venous thrombosis, nephropathies and placenta-associated obstetric complications in history, a high laboratory risk profile («double» and «triple» APA positivity; the presence of lupus anticoagulant, a higher titer of antibodies to cardiolipins and beta2-glycoprotein 1), as well as a higher score on the aGAPSS scale (7,3±3,5 vs 4,8±0,6 points, p <0,05).
Keywords: scale aGAPSS, antiphospholipid syndrome, antiphospholipid antibodies, thrombosis
Read entire article

Literature


  1. Cervera R. Antiphospholipid syndrome. Thrombosis Research. 2017; 151(S1): S43–S47. doi: 10.1016/S0049-3848(17)30066-X.

  2. Hancer V.S. Genetics of antiphospholipid syndrome. Human Genet Embryol. 2011; 1: e103. doi: 10.4172/2161-0436.1000e103.

  3. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2): 295–306.

  4. Sciascia S., Bertolaccini M.L. Thrombotic risk assessment in APS: the Global APS Score (GAPSS). Lupus. 2014; 23: 1286–87. doi: 10.1177/0961203314541317

  5. Sciascia S., Radin M., Sanna J., Cecchi I. et al. Clinical utility of the global antiphospholipid syndrome score for risk stratification: a pooled analysis. Rheumatology. 2018 Apr 1; 57(4): 661–65. doi: 10.1093/rheumatology/kex466.

  6. Vereina N.K., Sinitsyn S.P., Dolgushina V.F., Chulkov V.S. The difference in significance between antiphospholipid syndrome and antiphospholipid antibodies present in pregnant women with thrombosis and/or pregnancy complications. Thrombosis Research. 2015; 135(S1): S79. doi: 10.1016/S0049-3848(15)50448-9.

  7. Gebhart J., Posch F., Koder S., Quehenberger P. et al. High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant. Blood Adv. 2019; 3(5): 769–76. doi: 10.1182/bloodadvances.2018026948.

  8. De Carolis S., Tabacco S., Rizzo F., Giannini A. et al. Antiphospholipid syndrome: an update on risk factors for pregnancy outcome. Autoimmun Rev. 2018; 17(10): 956–66. doi: 10.1016/j.autrev.2018.03.018.

  9. Gris J.C., Bouvier S., Nouvellon E., Lissalde-Lavigneet G. et al. Antiphospholid antibodies and the risk of pregnancy complications. Thromb Res. 2017; 151(S.1): S34–S37. doi: 10.1016/S0049-3848(17)30064-6.

  10. Yelnik C.M., Laskin C.A., Porter T.F., Branch D.W. et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med. 2016; 3(1): e000131.doi: 10.1136/lupus-2015-000131.

  11. Ruiz-Irastorza G., Cuadrado M.J., Ruiz-Arruza I. et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task Force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011; 20: 206–18. doi: 10.1177/0961203310395803.

  12. Tektonidou M.G., Andreoli L., Limper M., Amoura Z. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019; 78: 1296–304. doi:10.1136/annrheumdis-2019-215213.

  13. Zuily S., de Laat B., Mohamed S., Kelchtermans H. et al. Validity of the global antiphospholipid syndrome score to predict thrombosis: A prospective multicentre cohort study. Rheumatology (Oxford). 2015; 54: 2071–75. doi:10.1093/rheumatology/kev238/

  14. Carmo A., Pego J., Mendes A. Thrombotic risk assessment in antiphospholipid syndrome. Thrombosis Research. 2019; 175(S.1): P.B434.

  15. Radin M., Sciascia S., Erkan D., Pengo V. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort. Semin. Arthriris Rheum. 2019 May 2. pii: S0049-0172(19)30090-3. doi: .1016/j.semarthrit.2019.04.009.


About the Autors

Natalya K. Vereina, MD, PhD, professor of the Department of faculty therapy of South Ural State medical University of the Ministry of Healthcare of Russia. Address: 454092, Chelyabinsk, 64 Vorovsky Str. Tel.: +7 (912) 407-21-95.
E-mail: vereinanata@yandex.ru
Vasiliy S. Chulkov, MD, PhD, professor of the Department of faculty therapy of South Ural State medical University of the Ministry of Healthcare of Russia. Address: 454092, Chelyabinsk, 64 Vorovsky Str. Tel.: +7 (922) 698-23-28.
E-mail: vschulkov@rambler.ru
Vladislav S. Chulkov, assistant of the Department of faculty therapy of South Ural State medical University of the Ministry of Healthcare of Russia. Address: 454092, Chelyabinsk, 64 Vorovsky Str. Tel.: +7 (950) 737-78-98.
E-mail: vlad.chulkov.1989@mail.ru
Tatyana V. Movchan, Senior laboratory assistant of the Department of faculty therapy of South Ural State medical University of the Ministry of Healthcare of Russia. Address: 454092, Chelyabinsk, 64 Vorovsky Str.
Tel.: +7 (351) 253-69-11. E-mail: ftherapy2017@gmail.com


Similar Articles

Back to Content

Бионика Медиа